Susan D. Demo
- Molecular Biology top 2%
- Oncology top 5%
- Cancer Research top 2%
- Hematology top 1%
- Immunology top 10%
- Co-authors
- Mark K. BennettGary YellenFrancesco ParlatiCongcong SunKevin D. ShenkChristopher J. KirkEvan R. LewisGuy J. Laidig
- Topics
- Ubiquitin and proteasome pathways (17 papers)Multiple Myeloma Research and Treatments (9 papers)Cancer-related Molecular Pathways (8 papers)
- Partner nations
- United StatesGermanySwitzerland
In The Last Decade
Susan D. Demo
37 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 101
- Molecular Biology 3.0k
- Oncology 901
- Cancer Research 825
- Hematology 724
- Immunology 411
Countries citing papers authored by Susan D. Demo
This map shows the geographic impact of Susan D. Demo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan D. Demo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan D. Demo more than expected).
Fields of papers citing papers by Susan D. Demo
This network shows the impact of papers produced by Susan D. Demo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan D. Demo. The network helps show where Susan D. Demo may publish in the future.
Co-authorship network of co-authors of Susan D. Demo
This figure shows the co-authorship network connecting the top 25 collaborators of Susan D. Demo. A scholar is included among the top collaborators of Susan D. Demo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan D. Demo. Susan D. Demo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 44 | |
| 3 | Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancerbreakdown → | 797 |
| 4 | 69 | |
| 5 | 62 | |
| 6 | 494 | |
| 7 | 3 | |
| 8 | Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasomebreakdown → | 542 |
| 9 | 6 | |
| 10 | 13 | |
| 11 | 51 | |
| 12 | 23 | |
| 13 | 58 | |
| 14 | 106 | |
| 15 | 46 | |
| 16 | 47 | |
| 17 | Signaling molecules that mediate the actions of FGF. | 6 |
| 18 | 271 | |
| 19 | 36 | |
| 20 | 26 |
About Susan D. Demo
Susan D. Demo is a scholar working on Hematology, Biochemistry and Oncology, having authored 38 papers that have together received 3.8k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (17 papers), Multiple Myeloma Research and Treatments (9 papers) and Cancer-related Molecular Pathways (8 papers). The work is most often cited by research in Hematology (724 citations), Cancer Research (825 citations) and Molecular Biology (3.0k citations). Susan D. Demo has collaborated with scholars based in United States, Germany and Switzerland. Frequent co-authors include Mark K. Bennett, Gary Yellen, Francesco Parlati, Congcong Sun, Kevin D. Shenk, Christopher J. Kirk, Evan R. Lewis, Guy J. Laidig, Peter J. Shwonek and Monette Aujay. Their work appears in journals such as Journal of Biological Chemistry, Nature Medicine and Neuron.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.